Related Experiment Video

Updated: Aug 10, 2025

Method of Direct Segmental Intra-hepatic Delivery Using a Rat Liver Hilar Clamp Model
09:22

Method of Direct Segmental Intra-hepatic Delivery Using a Rat Liver Hilar Clamp Model

Published on: April 2, 2017

14.2K

Fused human paraoxonase 1 as a prophylactic agent against organophosphate poisoning

Prakashkumar Dobariya1, Pratik Adhya2, Bhupesh Vaidya2

  • 1Department of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S.A.S. Nagar, Mohali 160062, Punjab, India.

Enzyme and Microbial Technology
|February 10, 2023
PubMed

Insights

Developing a novel human paraoxonase 1 (hPON1) variant offers a promising prophylactic strategy against organophosphate (OP) poisoning. This engineered enzyme demonstrates improved safety and efficacy in preventing OP toxicity and mortality.

Area of Science:

  • Biochemistry
  • Toxicology
  • Pharmacology

Background:

  • Organophosphates (OPs) are potent neurotoxins with significant implications for chemical warfare and terrorism.
  • Current treatments for OP poisoning exhibit limited efficacy and undesirable side effects, highlighting the urgent need for advanced prophylactic agents.
  • Human Paraoxonase 1 (hPON1) shows potential for OP detoxification due to its hydrolytic activity against OP compounds.

Purpose of the Study:

  • To engineer and characterize a novel variant of human paraoxonase 1 (hPON1) with enhanced prophylactic capabilities against organophosphate (OP) poisoning.
  • To improve the pharmacokinetic properties of hPON1 for better in vivo performance as a therapeutic agent.
  • To evaluate the efficacy of the engineered hPON1 variant in preventing OP-induced toxicity and mortality.

Main Methods:

  • Development of a fused hPON1 (FHP) variant through protein engineering.
  • Characterization of the FHP variant's enzymatic activity and pharmacokinetic profile in vivo.
  • Assessment of the FHP variant's protective effects against OP-poisoning in a rat model.

Main Results:

  • The engineered FHP variant exhibited significantly enhanced in vivo pharmacokinetic properties compared to wild-type hPON1.
  • Administration of the FHP variant effectively delayed or prevented the onset of OP-poisoning symptoms in rats.
  • The FHP variant demonstrated a remarkable ability to prevent OP-induced mortality in the experimental model.

Conclusions:

  • The developed FHP variant represents a promising new prophylactic agent for organophosphate poisoning.
  • Enhanced pharmacokinetic properties contribute to the improved efficacy of the FHP variant in vivo.
  • This engineered hPON1 offers a potentially safer and more effective strategy for mitigating the effects of OP exposure.
Keywords:
Fused human paraoxonase 1Human serum albuminOrganophosphate poisoningPharmacokineticProphylactic

More Related Videos

Novel Whole-tissue Quantitative Assay of Nitric Oxide Levels in Drosophila Neuroinflammatory Response07:49

Novel Whole-tissue Quantitative Assay of Nitric Oxide Levels in Drosophila Neuroinflammatory Response

Published on: December 4, 2013

8.0K
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

7.6K

Related Concept Videos

Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
959
Prevention of Further Absorption of Poison01:14

Prevention of Further Absorption of Poison

In cases of acute poisoning, the primary objective is to prevent further absorption of the toxic substance into the body. Immediate interventions using various decontamination techniques targeting the gastrointestinal (GI) tract can achieve this. Decontamination is crucial to prevent poison from entering the systemic circulation, which involves washing affected areas with water and mild soap and removing contaminated clothing. Once external decontamination is done, attention must be turned to...
894
Peroxisomes01:24

Peroxisomes

Peroxisomes are specialized organelles present in fungi, plant, and animal cells. It can vary in number, size, morphology, and activity depending on the type of tissue and the nutritional state of the cell. For example, cells with active lipid metabolism, such as adipocytes, neurons, and hepatocytes, have more peroxisomes than other cells in the body. Besides their primary role in breaking down complex organic molecules, peroxisomes can also synthesize specific macromolecules and participate in...
13.8K
Enhanced Elimination of Poison01:26

Enhanced Elimination of Poison

Poison can be effectively removed from the gastrointestinal (GI) tract through various decontamination procedures.
Antidotes serve a crucial role in counteracting the effects of poison by inhibiting enzymes responsible for producing harmful drug metabolites. In some cases, these toxic metabolites can be neutralized by endogenous cosubstrates, which are maintained at specific concentrations to prevent interaction with cellular macromolecules and subsequent cell death.
Renal excretion is the...
560
Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.0K
Indirect-Acting Cholinergic Agonists: Pharmacokinetics01:22

Indirect-Acting Cholinergic Agonists: Pharmacokinetics

Indirect-acting cholinergic agonists, or anticholinesterases, enhance the body's cholinergic activity by inhibiting acetylcholine's breakdown. They are categorized as reversible or irreversible agents based on their mechanism of action. They are further classified into short-acting, intermediate-acting, and long-acting agents based on their duration of action.
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
1.1K